Oliveira Beatriz Araujo, Oliveira Lea Campos de, Sabino Ester Cerdeira, Okay Thelma Suely
Universidade de São Paulo, Instituto de Medicina Tropical de São Paulo, Laboratório de Investigação Médica (LIM 46), São Paulo, São Paulo, Brazil.
Universidade de São Paulo, Instituto de Medicina Tropical de São Paulo, Laboratório de Soroepidemiologia e Imunologia, São Paulo, São Paulo, Brazil.
Rev Inst Med Trop Sao Paulo. 2020 Jun 29;62:e44. doi: 10.1590/S1678-9946202062044. eCollection 2020.
Coronavirus disease 2019 (COVID-19) is an infectious disease initially reported in China and currently worldwide dispersed caused by a new coronavirus (SARS-CoV-2 or 2019-nCoV) affecting more than seven million people around the world causing more than 400 thousand deaths (on June 8th, 2020). The diagnosis of COVID-19 is based on the clinical and epidemiological history of the patient. However, the gold standard for COVID-19 diagnosis is the viral detection through the amplification of nucleic acids. Although the quantitative Reverse-Transcription Polymerase Chain Reaction (RT-PCR) has been described as the gold standard for diagnosing COVID-19, there are several difficulties involving its use. Here we comment on RT-PCR and describe alternative tests developed for the diagnosis of COVID-19.
2019冠状病毒病（COVID-19）是一种最初在中国报告、目前已在全球传播的传染病，由一种新型冠状病毒（严重急性呼吸综合征冠状病毒2 或2019-nCoV）引起，全球感染人数超过700万，造成40多万人死亡（2020年6月8日数据）。COVID-19的诊断基于患者的临床和流行病学史。然而，COVID-19诊断的金标准是通过核酸扩增进行病毒检测。尽管定量逆转录聚合酶链反应（RT-PCR）已被描述为诊断COVID-19的金标准，但在使用过程中存在一些困难。在此，我们对RT-PCR进行评论，并描述为诊断COVID-19而开发的替代检测方法。
